KR101221640B1 - 자궁 종양 치료용 약제의 제조를 위한7-티-부톡시이미노메틸캄토테신의 용도 - Google Patents

자궁 종양 치료용 약제의 제조를 위한7-티-부톡시이미노메틸캄토테신의 용도 Download PDF

Info

Publication number
KR101221640B1
KR101221640B1 KR1020067027912A KR20067027912A KR101221640B1 KR 101221640 B1 KR101221640 B1 KR 101221640B1 KR 1020067027912 A KR1020067027912 A KR 1020067027912A KR 20067027912 A KR20067027912 A KR 20067027912A KR 101221640 B1 KR101221640 B1 KR 101221640B1
Authority
KR
South Korea
Prior art keywords
butoxyiminomethylcamptothecin
treatment
therapeutic agent
tumor
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020067027912A
Other languages
English (en)
Korean (ko)
Other versions
KR20070030246A (ko
Inventor
파올로 카르미나티
마르코 코르시
클라우디오 잔나
프랑코 카발리
루카 지아니
크리스티아나 세사
Original Assignee
시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. filed Critical 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이.
Publication of KR20070030246A publication Critical patent/KR20070030246A/ko
Application granted granted Critical
Publication of KR101221640B1 publication Critical patent/KR101221640B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020067027912A 2004-06-11 2005-06-08 자궁 종양 치료용 약제의 제조를 위한7-티-부톡시이미노메틸캄토테신의 용도 Expired - Fee Related KR101221640B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITRM2004A000288 2004-06-11
IT000288A ITRM20040288A1 (it) 2004-06-11 2004-06-11 Uso della 7-t-butossiimminometilcamptotecina per la preparazione di un medicamento per il trattamento delle neoplasie dell'utero.
PCT/IT2005/000320 WO2005120643A2 (en) 2004-06-11 2005-06-08 Use of 7-t-butoxyiminomethylcamptothecin for treating uterine neoplasms

Publications (2)

Publication Number Publication Date
KR20070030246A KR20070030246A (ko) 2007-03-15
KR101221640B1 true KR101221640B1 (ko) 2013-01-14

Family

ID=34979678

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067027912A Expired - Fee Related KR101221640B1 (ko) 2004-06-11 2005-06-08 자궁 종양 치료용 약제의 제조를 위한7-티-부톡시이미노메틸캄토테신의 용도

Country Status (23)

Country Link
US (1) US7700613B2 (enExample)
EP (1) EP1773451B1 (enExample)
JP (2) JP2008501785A (enExample)
KR (1) KR101221640B1 (enExample)
CN (2) CN1953784A (enExample)
AR (1) AR049220A1 (enExample)
AT (1) ATE521351T1 (enExample)
AU (1) AU2005251573B2 (enExample)
BR (1) BRPI0511931A (enExample)
CA (1) CA2565213C (enExample)
CY (1) CY1112032T1 (enExample)
DK (1) DK1773451T3 (enExample)
ES (1) ES2372056T3 (enExample)
HK (1) HK1205951A1 (enExample)
HR (1) HRP20110718T1 (enExample)
IT (1) ITRM20040288A1 (enExample)
MX (1) MXPA06014162A (enExample)
PL (1) PL1773451T3 (enExample)
PT (1) PT1773451E (enExample)
RS (1) RS52038B (enExample)
SI (1) SI1773451T1 (enExample)
TW (1) TWI351283B (enExample)
WO (1) WO2005120643A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080213385A1 (en) * 2005-08-10 2008-09-04 Oskar Kalb Formulations for 7- (T-Butoxy) Iminomethyl Camptothecin
AU2008210511A1 (en) * 2007-02-01 2008-08-07 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Pharmaceutical composition comprising a campothecin derivative

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040018988A1 (en) * 1999-03-09 2004-01-29 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Camptothecin derivatives having antitumor activity

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757514B1 (fr) * 1996-12-20 1999-02-12 Sod Conseils Rech Applic Nouveaux analogues de la camptothecine, des procedes de preparation, leur application comme medicaments et les compositions pharmaceutiques les contenant
DE69635560T2 (de) * 1995-06-21 2006-08-17 Société de Conseils de Recherches et D'Applications Scientifiques (S.C.R.A.S.) Camptothecinanaloge, Verfahren zur ihrer Herstellung, ihre Verwendung als Arzneimittel und diese enthaltende pharmazeutische Zusammensetzungen
UA57757C2 (uk) * 1996-12-20 2003-07-15 Сос'Єте Де Консей Де Решерш Е Даплікасьон С'Єнтіфік (С.К.Р.А.С.) Аналоги камптотецину, спосіб їх отримання (варіанти) і фармацевтична композиція
DK1044977T3 (da) 1999-03-09 2002-07-08 Sigma Tau Ind Farmaceuti Camptothecinderivater med antitumoraktivitet
IT1306129B1 (it) * 1999-04-13 2001-05-30 Sigma Tau Ind Farmaceuti Esteri della l-carnitina o di alcanoil l-carnitine utilizzabili comelipidi cationici per l'immissione intracellulare di composti
US6352996B1 (en) * 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
WO2003043584A2 (en) 2001-11-20 2003-05-30 University Of Kentucky Research Foundation Engineered liposomal particles containing core-loaded pro-drugs for the controlled release of camptothecins
WO2004103358A2 (en) * 2003-05-21 2004-12-02 Novartis Ag Combination of histone deacetylase inhibitors with chemotherapeutic agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040018988A1 (en) * 1999-03-09 2004-01-29 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Camptothecin derivatives having antitumor activity

Also Published As

Publication number Publication date
TWI351283B (en) 2011-11-01
CN1953784A (zh) 2007-04-25
SI1773451T1 (sl) 2012-01-31
JP2008501785A (ja) 2008-01-24
ES2372056T3 (es) 2012-01-13
WO2005120643A8 (en) 2006-12-14
BRPI0511931A (pt) 2008-01-22
CA2565213C (en) 2012-08-07
CA2565213A1 (en) 2005-12-22
AU2005251573B2 (en) 2010-04-15
CY1112032T1 (el) 2015-11-04
ITRM20040288A1 (it) 2004-09-11
PT1773451E (pt) 2011-11-02
JP2014231518A (ja) 2014-12-11
AR049220A1 (es) 2006-07-05
WO2005120643A3 (en) 2006-03-30
CN104352496A (zh) 2015-02-18
AU2005251573A1 (en) 2005-12-22
US7700613B2 (en) 2010-04-20
DK1773451T3 (da) 2011-11-28
WO2005120643A2 (en) 2005-12-22
MXPA06014162A (es) 2007-03-07
EP1773451A2 (en) 2007-04-18
EP1773451B1 (en) 2011-08-24
US20080020030A1 (en) 2008-01-24
RS52038B (sr) 2012-04-30
HRP20110718T1 (hr) 2011-12-31
KR20070030246A (ko) 2007-03-15
TW200605891A (en) 2006-02-16
ATE521351T1 (de) 2011-09-15
HK1205951A1 (en) 2015-12-31
PL1773451T3 (pl) 2012-01-31

Similar Documents

Publication Publication Date Title
EP3013335B1 (en) Combination therapy for the treatment of cancer comprising eribulin and lenvatinib
EP2785349B2 (en) Combination treatment of cancer
RU2401662C2 (ru) Фармацевтические композиции и способы лечения рака и его метастазов
ITMI20001107A1 (it) Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel
EP4110326B1 (en) Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
KR102466192B1 (ko) 간세포성 암종의 치료를 위한 조합 요법
CN108366975A (zh) 使用脱氧胆酸和其盐对堆积的脂肪的治疗
JP2024539476A5 (enExample)
JP4128872B2 (ja) 癌治療法
CN113329749B (zh) 用于治疗葡萄膜黑色素瘤的联合疗法
TW202114694A (zh) 四環化合物及其鹽類、組合物、及彼等之使用方法
US20080207644A1 (en) Therapeutic materials and methods
HK1205951A1 (en) Use of 7-t-butoxyiminomethylcamptothecin for the prepartion of a medicament for the treatment of uterine neoplasms
HK1104002A (en) Use of 7-t-butoxyiminomethylcamptothecin for treating uterine neoplasms
AU2005219034A1 (en) Cancer treatment with topoisomerase-II inhibitor, a bis-dioxypiperazine and radiation
HK40061016A (en) Combination therapy for the treatment of uveal melanoma
WO2004073719A1 (en) A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent
JPS59134722A (ja) 出血性梗塞予防・治療剤

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20151224

Year of fee payment: 4

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20161229

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20171227

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20210108

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20210108